Physician profile
Randy R Calegari
NPI 1336263953
$2,550.02
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $290 · 2023: $204 · 2024: $14.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $223.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $182.13 | 2019-2024 | |
| Astellas Pharma US INC | $176.10 | 2019-2020 | |
| Amgen INC. | $173.68 | 2019-2020 | |
| Abbvie INC. | $171.38 | 2019-2023 | Epkinly |
| Janssen Biotech, INC. | $164.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $140.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $133.32 | 2019-2020 | |
| Pfizer INC. | $119.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $104.43 | 2019 | |
| Emd Serono, INC. | $71.38 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.18 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $55.95 | 2019 | |
| Eisai INC. | $52.50 | 2019 | |
| Foundation Medicine, INC. | $50.74 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.27 | 2019 | |
| Daiichi Sankyo INC. | $46.05 | 2019-2020 | |
| Puma Biotechnology, INC. | $45.50 | 2019-2020 | |
| Seagen INC. | $41.95 | 2019-2023 | Tukysa |
| Octapharma USA, INC. | $35.97 | 2019 | |
| Tesaro, INC. | $35.50 | 2019 | |
| Celgene Corporation | $35.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.19 | 2019-2020 | |
| Clovis Oncology, INC. | $32.71 | 2019-2020 | |
| Incyte Corporation | $30.48 | 2019 | |
| Genzyme Corporation | $30.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.82 | 2019 | |
| Karyopharm Therapeutics INC. | $24.38 | 2023 | Xpovio |
| Amag Pharmaceuticals, INC. | $23.56 | 2019 | |
| Taiho Oncology, INC. | $20.55 | 2019 | |
| Dova Pharmaceuticals | $20.30 | 2020 | |
| Glaxosmithkline, LLC. | $18.81 | 2020 | |
| Janssen Scientific Affairs, LLC | $17.05 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.03 | 2019 | |
| Heron Therapeutics, INC. | $16.55 | 2019 | |
| Verastem, INC. | $15.11 | 2019 | |
| Genentech USA, INC. | $14.40 | 2019 | |
| Dendreon Pharmaceuticals LLC | $12.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Calegari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.